CoChat
Sign Up
Cited by 778Alzheimer's disease research and treatmentsPrion Diseases and Protein MisfoldingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers

Open access
Kayed, Rakez, Head, Elizabeth, Sarsoza, Floyd, Saing, Tommy, Cotman, Carl W, Necula, Mihaela, Margol, Lawrence, Wu, Jessica, Breydo, Leonid, Thompson, Jennifer L, Rasool, Suhail, Gurlo, Tatyana, Butler, Peter, Glabe, Charles G·2007·Molecular Neurodegeneration
DOI 10.1186/1750-1326-2-18PMC PMC2100048
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Amyloid-related degenerative diseases are associated with the accumulation of misfolded proteins as amyloid fibrils in tissue. In Alzheimer disease (AD), amyloid accumulates in several distinct types of insoluble plaque deposits, intracellular Aβ and as soluble oligomers and the relationships between these deposits and their pathological significance remains unclear. Conformation dependent antibodies have been reported that specifically recognize distinct assembly states of amyloids, including prefibrillar oligomers and fibrils. Results: We immunized rabbits with a morphologically homogeneous population of Aβ42 fibrils. The resulting immune serum (OC) specifically recognizes fibrils, but not random coil monomer or prefibrillar oligomers, indicating fibrils display a distinct conformation dependent epitope that is absent in prefibrillar oligomers. The fibril epitope is also displayed by fibrils of other types of amyloids, indicating that the epitope is a generic feature of the polypeptide backbone. The fibril specific antibody also recognizes 100,000 × G soluble fibrillar oligomers ranging in size from dimer to greater than 250 kDa on western blots. The fibrillar oligomers recognized by OC are immunologically distinct from prefibrillar oligomers recognized by A11, even though their sizes overlap broadly, indicating that size is not a reliable indicator of oligomer conformation. The immune response to prefibrillar oligomers and fibrils is not sequence specific and antisera of the same specificity are produced in response to immunization with islet amyloid polypeptide prefibrillar oligomer mimics and fibrils. The fibril specific antibodies stain all types of amyloid deposits in human AD brain. Diffuse amyloid deposits stain intensely with anti-fibril antibody although they are thioflavin S negative, suggesting that they are indeed fibrillar in conformation. OC also stains islet amyloid deposits in transgenic mouse models of type II diabetes, demonstrating its generic specificity for amyloid fibrils. Conclusion: Since the fibril specific antibodies are conformation dependent, sequence-independent, and recognize epitopes that are distinct from those present in prefibrillar oligomers, they may have broad utility for detecting and characterizing the accumulation of amyloid fibrils and fibrillar type oligomers in degenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1750-1326-2-18

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characterization of OC antiserum. A. ELISA analysis. Plates were coated with homogenous samples of Aβ fibrils, Aβ monomer, Aβ prefibrillar oligomers, and α-synuclein and IAPP fibrils. The samples were reacted with OC serum which indicates that all types of fibrils and not Aβ monomer or prefibrillar oligomers react with OC. B. Dot blot analysis of Aβ42 and polyQ36 prefibrillar oligomers and fibrils. Aβ42 and polyQ fibrils only stain with OC serum, while Aβ42 and polyQ prefibrillar oligomers only react with A11.
Figure 1 Characterization of OC antiserum. A. ELISA analysis. Plates were coated with homogenous samples of Aβ fibrils, Aβ monomer, Aβ prefibrillar oligomers, and α-synuclein and IAPP fibrils. The samples were reacted with OC serum which indicates that all types of fibrils and not Aβ monomer or prefibrillar oligomers react with OC. B. Dot blot analysis of Aβ42 and polyQ36 prefibrillar oligomers and fibrils. Aβ42 and polyQ fibrils only stain with OC serum, while Aβ42 and polyQ prefibrillar oligomers only react with A11.CC BY · PubMed Central
Figure 2 Western blot analysis of Aβ42 fibrils and prefibrillar oligomers. Aβ42 fibrils (F) and prefibrillar oligomers (O) were run on SDS polyacrylamide gels, transferred to nitrocellulose and probed with 6E10, 4G8, OC and A11 antibodies as indicated at the top of the panel. Both fibrillar and prefibrillar oligomer samples contain bands that react with 4G8 ranging from monomer up to the size of material that accumulates at the top of the gel. OC only stains the bands from fibrillar samples of approximately dimer and above. A11 only stains the prefibrillar oligomer samples. 6E10 does not stain prefibrillar Aβ oligomer samples formed at pH 7.4 as previously reported [22].
Figure 2 Western blot analysis of Aβ42 fibrils and prefibrillar oligomers. Aβ42 fibrils (F) and prefibrillar oligomers (O) were run on SDS polyacrylamide gels, transferred to nitrocellulose and probed with 6E10, 4G8, OC and A11 antibodies as indicated at the top of the panel. Both fibrillar and prefibrillar oligomer samples contain bands that react with 4G8 ranging from monomer up to the size of material that accumulates at the top of the gel. OC only stains the bands from fibrillar samples of approximately dimer and above. A11 only stains the prefibrillar oligomer samples. 6E10 does not stain prefibrillar Aβ oligomer samples formed at pH 7.4 as previously reported [22].CC BY · PubMed Central
Figure 3 Solubility and size distribution of fibrillar Aβ42 oligomers under physiological conditions. A. Aβ42 aggregates were prepared in HFIP-H20 and DMSO-F12 medium as described in Materials and Methods and centrifuged at 100,000 × G for 1 hr. The supernatant and pellet fractions were separated and the pellet resuspended in an equal volume of PBS. Aliquots of the supernatant and pellet were dotted on nitrocellulose and probed with OC antisera. Both the soluble and insoluble fractions contain significant amounts of OC reactive material. B. Aβ42 aggregates formed in DMSO were fractionated by size exclusion chromatography on a Toso-Haas 2000 SWXL column, 1 minute fractions collected and dotted on nitrocellulose and probed with OC antisera. The elution profile detected by UV absorbance is shown in the top panel. The bottom panel shows the OC immunoreactivity which is detected in fractions from 8–14 minutes, indicating that low MW Aβ oligomers are immunoreactive with OC. The arrows indicate the positions of the void volume (Vo), included volume (Vi) and the elution positions of molecular weight standards.
Figure 3 Solubility and size distribution of fibrillar Aβ42 oligomers under physiological conditions. A. Aβ42 aggregates were prepared in HFIP-H20 and DMSO-F12 medium as described in Materials and Methods and centrifuged at 100,000 × G for 1 hr. The supernatant and pellet fractions were separated and the pellet resuspended in an equal volume of PBS. Aliquots of the supernatant and pellet were dotted on nitrocellulose and probed with OC antisera. Both the soluble and insoluble fractions contain significant amounts of OC reactive material. B. Aβ42 aggregates formed in DMSO were fractionated by size exclusion chromatography on a Toso-Haas 2000 SWXL column, 1 minute fractions collected and dotted on nitrocellulose and probed with OC antisera. The elution profile detected by UV absorbance is shown in the top panel. The bottom panel shows the OC immunoreactivity which is detected in fractions from 8–14 minutes, indicating that low MW Aβ oligomers are immunoreactive with OC. The arrows indicate the positions of the void volume (Vo), included volume (Vi) and the elution positions of molecular weight standards.CC BY · PubMed Central
Figure 4 Comparison of A11 and I11 antibody specificity. A. Dot blots. Aβ monomer, Aβ prefibrillar oligomers (prepared in HFIP-H20, pH 2.5), Aβ fibrils and α-synuclein and IAPP prefibrillar oligomers were spotted on nitrocellulose strips and probed with A11, I11 and 6E10 as a control. A11 and I11 antibodies demonstrate the same specificity for prefibrillar oligomers and do not react with monomer or fibrils. 6E10 stains the Aβ-containing samples, including prefibrillar oligomers formed at acid pH. B. Western blots. Prefibrillar oligomer samples of calcitonin (Lane 1), insulin (Lane 2) and prion peptide 106–126 (Lane 3) were probed with A11 and I11, which give the same staining pattern.
Figure 4 Comparison of A11 and I11 antibody specificity. A. Dot blots. Aβ monomer, Aβ prefibrillar oligomers (prepared in HFIP-H20, pH 2.5), Aβ fibrils and α-synuclein and IAPP prefibrillar oligomers were spotted on nitrocellulose strips and probed with A11, I11 and 6E10 as a control. A11 and I11 antibodies demonstrate the same specificity for prefibrillar oligomers and do not react with monomer or fibrils. 6E10 stains the Aβ-containing samples, including prefibrillar oligomers formed at acid pH. B. Western blots. Prefibrillar oligomer samples of calcitonin (Lane 1), insulin (Lane 2) and prion peptide 106–126 (Lane 3) were probed with A11 and I11, which give the same staining pattern.CC BY · PubMed Central
Figure 5 Comparison of LOC and OC antisera specificity. Aβ monomer, prefibrillar oligomers and fibrils were spotted on nitrocellulose strips and probed with LOC and OC antisera. Both LOC and OC react only with fibrillar samples.
Figure 5 Comparison of LOC and OC antisera specificity. Aβ monomer, prefibrillar oligomers and fibrils were spotted on nitrocellulose strips and probed with LOC and OC antisera. Both LOC and OC react only with fibrillar samples.CC BY · PubMed Central
Figure 6 Immunolabeling characteristics of OC in an AD case and preabsorption controls. Extensive OC labeling was observed in the hippocampus (A), subiculum (B) and frontal cortex (C) in AD. A higher magnification photograph illustrates that OC positive deposits were dense and consisted of fine fibrillar material (D). Preabsorption with a 100-fold concentration of OC antigen leads to a significant reduction in immunolabeling in the frontal cortex (E &F). Significant overlap was observed between OC positive immunoreactivity (Red – G) and LOC positive immunoreactivity (Green-H) suggesting that the two antibodies recognize similar deposits (Overlap is yellow – I). Magnification in A, B, C – 1.25×, D – 20×, E, F – 4× and G, H, I – 40×.
Figure 6 Immunolabeling characteristics of OC in an AD case and preabsorption controls. Extensive OC labeling was observed in the hippocampus (A), subiculum (B) and frontal cortex (C) in AD. A higher magnification photograph illustrates that OC positive deposits were dense and consisted of fine fibrillar material (D). Preabsorption with a 100-fold concentration of OC antigen leads to a significant reduction in immunolabeling in the frontal cortex (E &F). Significant overlap was observed between OC positive immunoreactivity (Red – G) and LOC positive immunoreactivity (Green-H) suggesting that the two antibodies recognize similar deposits (Overlap is yellow – I). Magnification in A, B, C – 1.25×, D – 20×, E, F – 4× and G, H, I – 40×.CC BY · PubMed Central
Figure 7 Western blot analysis of Triton X-100 insoluble fractions from human AD brain lysates. Frontal cortex samples, either untreated or formic acid treated, from 6 individual AD brains were dissolved in SDS sample buffer and electrophoresed on polyacrylamide gels and probed with OC or 4G8 as a control. Upper panels: For untreated samples, both OC and 4G8 detect high molecular weight material that accumulates at the top of the gel. Bottom panels: After formic acid treatment, 4G8 detects some lower MW bands in addition to formic acid resistant high MW material, while the staining by OC is abolished, indicating that the staining is conformation dependent.
Figure 7 Western blot analysis of Triton X-100 insoluble fractions from human AD brain lysates. Frontal cortex samples, either untreated or formic acid treated, from 6 individual AD brains were dissolved in SDS sample buffer and electrophoresed on polyacrylamide gels and probed with OC or 4G8 as a control. Upper panels: For untreated samples, both OC and 4G8 detect high molecular weight material that accumulates at the top of the gel. Bottom panels: After formic acid treatment, 4G8 detects some lower MW bands in addition to formic acid resistant high MW material, while the staining by OC is abolished, indicating that the staining is conformation dependent.CC BY · PubMed Central
Figure 8 OC staining of pancreatic section from Tg mouse model of type II diabetes expressing human IAPP (obese hemizygous human IAPP transgenic mouse). OC labeling (red) was detected within the islets in insulin-positive (green) beta cells and in the extracellular amyloid deposits.
Figure 8 OC staining of pancreatic section from Tg mouse model of type II diabetes expressing human IAPP (obese hemizygous human IAPP transgenic mouse). OC labeling (red) was detected within the islets in insulin-positive (green) beta cells and in the extracellular amyloid deposits.CC BY · PubMed Central
Figure 9 Schematic representation of the distinct types of amyloid oligomers and their relationships to amyloid fibrils. Amyloid aggregation pathways begin with misfolded amyloidogenic monomer (top) and can diverge in two directions depending on which conformation it adopts. It can aggregate to form prefibrillar oligomers by adopting the conformation recognized by A11 (left pathway). These prefibrillar oligomers then align to form protofibrils (not shown) and undergo another conformation change "en bloc" to form fibrils. They are termed prefibrillar oligomers because they are transient intermediates that ultimately become fibrils. Alternatively, amyloidogenic monomer can aggregate to adopt a fibrillar conformation recognized by OC antibody (right pathway). The resulting fibrillar oligomers may represent fibril nuclei which are the minimal stable aggregate that is capable of elongating by recruiting additional monomers. Addition of monomers on to the ends of fibrillar oligomers and fibrils result in fibril growth. The distinction between fibrillar oligomers and fibrils is based on an arbitrary size difference as no conformation difference is apparent. Fibrils may be distinct from fibrillar oligomers on the basis of their content of multiple protofilaments (not shown) but this does not necessarily imply a necessary conformation difference in their integral peptide constituents.
Figure 9 Schematic representation of the distinct types of amyloid oligomers and their relationships to amyloid fibrils. Amyloid aggregation pathways begin with misfolded amyloidogenic monomer (top) and can diverge in two directions depending on which conformation it adopts. It can aggregate to form prefibrillar oligomers by adopting the conformation recognized by A11 (left pathway). These prefibrillar oligomers then align to form protofibrils (not shown) and undergo another conformation change "en bloc" to form fibrils. They are termed prefibrillar oligomers because they are transient intermediates that ultimately become fibrils. Alternatively, amyloidogenic monomer can aggregate to adopt a fibrillar conformation recognized by OC antibody (right pathway). The resulting fibrillar oligomers may represent fibril nuclei which are the minimal stable aggregate that is capable of elongating by recruiting additional monomers. Addition of monomers on to the ends of fibrillar oligomers and fibrils result in fibril growth. The distinction between fibrillar oligomers and fibrils is based on an arbitrary size difference as no conformation difference is apparent. Fibrils may be distinct from fibrillar oligomers on the basis of their content of multiple protofilaments (not shown) but this does not necessarily imply a necessary conformation difference in their integral peptide constituents.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Wisniewski HM, Terry RD: Reexamination of the pathogenesis of the senile plaque. Prog Neuropathol. 1973, 333 , 2: 1-26.

Cited by

Sorted by citations

See all 778

Related

Metadata

Authors
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., & Glabe, C. G.
Affiliations
  • University of California, Irvine (US)
  • University of California, Los Angeles (US)
Corresponding author
Glabe, Charles G
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2007-09-26
Volume
2
Issue
1
Pages
18-18
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/1750-1326-2-18
PMC
PMC2100048
OpenAlex
W2156193029
Cited by
773
References
28
Citations by year
2026: 21 · 2025: 35 · 2024: 36 · 2023: 42 · 2022: 32 · 2021: 41 · 2020: 57 · 2019: 35 · 2018: 44 · 2017: 40 · 2016: 43 · 2015: 52 · 2014: 45 · 2013: 65 · 2012: 59
FWCI
18.92
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Larry L. Hillblom Foundation
  • Cure Alzheimer's Fund
  • National Institutes of Health (AG16573, AG000538)
  • National Institute on Aging (P01AG000538, P50 AG 16573, AG 16573, AG-000538, P50AG016573)
  • National Institute of Neurological Disorders and Stroke (R01NS031230)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid fibrils, prefibrillar oligomers, epitope mapping, amyloid-beta 42, Alzheimer's disease, amylin, type 2 diabetes, amyloid deposits, immunization, thioflavin S, degenerative diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review